Tilray Brands (NASDAQ:TLRY) Upgraded to “Hold” at Wall Street Zen

Wall Street Zen upgraded shares of Tilray Brands (NASDAQ:TLRY) from a sell rating to a hold rating in a report published on Saturday.

Other research analysts have also issued research reports about the stock. Canaccord Genuity Group assumed coverage on shares of Tilray Brands in a research note on Tuesday, January 27th. They issued a “hold” rating for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tilray Brands in a research note on Wednesday, January 21st. Zacks Research upgraded shares of Tilray Brands from a “strong sell” rating to a “hold” rating in a report on Wednesday, February 11th. ATB Cormark Capital Markets raised shares of Tilray Brands from a “strong sell” rating to a “hold” rating in a research report on Wednesday, December 10th. Finally, Roth Mkm dropped their price target on shares of Tilray Brands from $20.00 to $10.00 and set a “neutral” rating for the company in a research note on Tuesday, January 20th. One equities research analyst has rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $13.33.

Tilray Brands Price Performance

TLRY stock opened at $6.21 on Friday. The business’s fifty day moving average price is $7.83 and its 200 day moving average price is $10.52. Tilray Brands has a 12-month low of $3.51 and a 12-month high of $23.20. The company has a current ratio of 2.81, a quick ratio of 1.72 and a debt-to-equity ratio of 0.19. The company has a market capitalization of $723.53 million, a PE ratio of -0.28 and a beta of 1.96.

Tilray Brands (NASDAQ:TLRY) last announced its earnings results on Thursday, January 8th. The company reported ($0.02) EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.12. The company had revenue of $217.51 million during the quarter, compared to analysts’ expectations of $211.15 million. Tilray Brands had a negative return on equity of 6.35% and a negative net margin of 251.69%.During the same period last year, the business posted ($0.03) EPS. On average, sell-side analysts anticipate that Tilray Brands will post -0.2 EPS for the current year.

Hedge Funds Weigh In On Tilray Brands

Institutional investors and hedge funds have recently made changes to their positions in the stock. Hilton Head Capital Partners LLC acquired a new position in shares of Tilray Brands during the fourth quarter worth $38,000. Engineers Gate Manager LP acquired a new position in Tilray Brands in the fourth quarter valued at approximately $126,000. Oppenheimer & Co. Inc. acquired a new position in Tilray Brands in the third quarter valued at approximately $25,000. Silverlake Wealth Management LLC purchased a new position in Tilray Brands in the third quarter valued at approximately $25,000. Finally, Unified Investment Management purchased a new position in Tilray Brands in the third quarter valued at approximately $26,000. 9.35% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Tilray Brands

Here are the key news stories impacting Tilray Brands this week:

• Positive Sentiment: Tilray Medical announced its largest medical-cannabis portfolio expansion in Australia, reinforcing patient access and signaling commitment to a growth market — a revenue and patient-share catalyst for TLRY’s medical segment. Tilray Medical Announces Major Expansion of Medical Cannabis Portfolio in Australia
• Positive Sentiment: Tilray Medical, CC Pharma and 14U Pharma formed a strategic alliance with “gesund leben” and Alliance Healthcare Deutschland to accelerate market expansion in Germany — a distribution and commercialization boost for EU sales. Tilray Medical, CC Pharma, and 14U Pharma Announce Strategic Alliance
• Positive Sentiment: CEO Irwin Simon told Just Drinks the company is focused on “putting stability in place” for BrewDog — signaling management attention on operational turnaround and margin stabilization in its beverage segment. “We need to put stability in place” – Tilray Brands CEO on what lies ahead for BrewDog
• Neutral Sentiment: Market write-ups note TLRY is slipping more than the broader market in recent sessions—useful short-term context but largely descriptive of current flow rather than new fundamental news. Tilray Brands, Inc. (TLRY) Dips More Than Broader Market: What You Should Know
• Negative Sentiment: Technical analysts warn TLRY has lost a key support level and suggest downside toward ~$5 is possible if selling continues — a short-term bearish signal that can amplify downside as stops trigger. Tilray stock price has just lost a key support: is a crash to $5 coming?

About Tilray Brands

Tilray Brands, Inc is a global cannabis-lifestyle and consumer packaged goods company engaged in the cultivation, production, distribution and sale of cannabis and cannabinoid-based products. The company develops and markets a diverse portfolio of branded products spanning medical cannabis, adult-use recreational products and wellness offerings. Through state-of-the-art cultivation facilities, research and development efforts, and quality control systems, Tilray Brands aims to deliver consistent, scalable products for a range of patient and consumer needs.

Tilray’s product lineup includes cannabis flower, pre-rolls, oils and tinctures, vapes, edibles and topicals, as well as hemp-derived cannabidiol (CBD) products.